Protectionist Economic Policies Create Roadblocks For Foreign Companies In China, Says U.S. Treasury Secretary
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As the U.S. Senate held hearings on the Chinese exchange rate and overall economic policies that are said to be underlying an immense trade imbalance and blocking American businesses from competing freely in China, Treasury Secretary Timothy Geithner outlined an array of new and potential countermeasures
You may also be interested in...
China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce
BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China
China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce
BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China
China's Delays In Approving Clinical Trials, Poor IP Protections Block Access To Innovative Drugs - EU Chamber Of Commerce
Excellent clinical trial centers and a good medical infrastructure make China well-qualified to better integrate global clinical trials, increase cooperation with world-class clinicians and speed up the regulatory process, according to an EU Chamber position paper.